Inactive Instrument

Zogenix, Inc.

ZGNX

US98978L2043

Zogenix to Release Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7

October 31, 2017 at 08:01 am EDT

EMERYVILLE, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September 30, 2017, after the market close, and will host a corporate update conference call and webcast on Tuesday, November 7, 2017 at 4:30 PM Eastern Time.

Tuesday, November 7^th @ 4:30 PM Eastern Time/1:30 PM Pacific Time
Toll Free:                   888-211-9963
International:            719-325-4773
Conference ID:         6163936
Webcast:                    http://public.viavid.com/index.php?id=126700

Replays, available through November 21, 2017:
Domestic:                  844-512-2921
International:            412-317-6671
Replay PIN:               6163936

About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

For more information, visit www.zogenix.com.

CONTACT: Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com

Latest news about Zogenix, Inc.

Pulmocide Announces Expansion of Management Team	23-06-08	CI
U.S. FDA approves UCB's drug for rare childhood epilepsy	22-03-28	RE
Zogenix Completes $1.9 Billion Buyout by UCB; Shares Delisted From Nasdaq	22-03-07	MT
UCB Closes Zogenix Acquisition for Nearly $1.9 Billion	22-03-07	MT
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from NASDAQ Composite Index	22-03-07	CI
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from S&P Pharmaceuticals Select Industry Index	22-03-07	CI
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from S&P TMI Index	22-03-07	CI
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from S&P Global BMI Index	22-03-07	CI
UCB BioSciences, Inc. completed the acquisition of Zogenix, Inc..	22-03-03	CI
Zogenix, Inc.(NasdaqGM:ZGNX) dropped from NASDAQ Biotechnology Index	22-03-01	CI
Northland Downgrades Zogenix to Market Perform From Outperform, Lifts Price Target to $27 From $26	22-02-28	MT
Zogenix Q4 Loss Narrows, Revenue Increases	22-02-28	MT
Zogenix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-28	CI
Zogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-28	CI
Earnings Flash (ZGNX) ZOGENIX Posts Q4 Revenue $26.6M	22-02-28	MT
Health Care Stocks Floundering Late in Wednesday Trading	22-01-19	MT
JMP Securities Downgrades Zogenix to Market Perform From Market Outperform	22-01-19	MT
Top Midday Gainers	22-01-19	MT
Health Care Stocks Moderately Higher Wednesday Afternoon	22-01-19	MT
Needham & Co Downgrades Zogenix to Hold From Buy	22-01-19	MT
Guggenheim Downgrades Zogenix to Neutral From Buy, Adjusts Price Target to $28 From $35	22-01-19	MT
William Blair Downgrades Zogenix to Market Perform From Outperform	22-01-19	MT
Zogenix Agrees to $1.9 Billion Takeover by UCB; Shares Surge	22-01-19	MT
Wall Street Set for Recovery After Bond Yield-Induced Sell-Off	22-01-19	MT
Health Care Stocks Edge Higher Premarket Wednesday	22-01-19	MT

Chart Zogenix, Inc.

Duration

Period

More charts

Company Profile

Zogenix Inc is a United States-based biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for rare diseases. It is primarily focused on developing and commercializing two therapeutic product opportunities: Fintepla and MT1621. Its first rare disease therapy, Fintepla is an oral solution, developed for the treatment of seizures associated with Dravet syndrome, a rare, devastating, severe lifelong epilepsy. The Company also has two late-stage development programs underway, one for Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare childhood-onset epilepsy. MT1621 is an investigational deoxynucleoside-combination substrate enhancement therapy in development for the treatment of TK2d, an inherited mitochondrial deoxyribonucleic acid depletion disease that predominantly affects children and is often fatal.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-4.66%	87.53B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.42B
BIOGEN INC.	-20.34%	29.48B
UCB	+57.16%	25.43B
INCYTE CORPORATION	-17.87%	11.49B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.3B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.1B
SWEDISH ORPHAN BIOVITRUM AB	+4.27%	8.75B
INNOVENT BIOLOGICS, INC.	-8.42%	7.99B

Biopharmaceuticals